Te­va’s an­tipsy­chot­ic as­set pass­es Phase 3 test in schiz­o­phre­nia

Te­va said Wednes­day morn­ing that its schiz­o­phre­nia drug suc­ceed­ed in a Phase 3 tri­al with signs of a dif­fer­en­ti­at­ed safe­ty pro­file ver­sus stan­dard of care …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER